Skip to content
10-Q

Quarterly Report

GT Biopharma, Inc. GTBP

0001493152-26-023346

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 8, 2026 36.06M sh
Shares Diluted Q1 2026 · Mar 31, 2026 30.28M sh
Shares Diluted Q1 2026 · Mar 31, 2025 2.35M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$2.47M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$2.2M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $8.92M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $6.81M
Stockholders Equity Q1 2026 · Mar 31, 2026 $7.58M
Stockholders Equity Q1 2026 · Dec 31, 2025 $5.79M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$980K
Stockholders Equity Q1 2026 · Dec 31, 2024 −$1.67M
Current Liabilities Q1 2026 · Mar 31, 2026 $2.42M
Current Liabilities Q1 2026 · Dec 31, 2025 $2.32M
Current Assets Q1 2026 · Mar 31, 2026 $10M
Current Assets Q1 2026 · Dec 31, 2025 $8.11M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.11
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.33
Eps Basic Q1 2026 · Mar 31, 2026 −$0.11
Eps Basic Q1 2026 · Mar 31, 2025 −$0.33
Sga Expense Q1 2026 · Mar 31, 2026 $2.44M
Sga Expense Q1 2026 · Mar 31, 2025 $833K
Rd Expense Q1 2026 · Mar 31, 2026 $413K
Rd Expense Q1 2026 · Mar 31, 2025 $1.1M
Net Income Q1 2026 · Mar 31, 2026 −$2.83M
Net Income Q1 2026 · Mar 31, 2025 −$776K
Operating Income Q1 2026 · Mar 31, 2026 −$2.85M
Operating Income Q1 2026 · Mar 31, 2025 −$1.93M